The analysis showed that the highest expression of survivin was found in the ovarian carcinoma group, in 78.0% (1448/1856) patients, with a lower expression found in the borderline group (45.7%; 59/129), and the lowest in the benign group (21.7%; 46/212). This evidence concerns the gene BIRC5 and ovarian carcinoma.